Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
Authors
Keywords
Advanced hepatocellular carcinoma, Immune checkpoint inhibitors, Cytokines, Adoptive cell transfer, Oncolytic virus, Vaccines, Immune-related toxicity
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 157, Issue -, Pages 103167
Publisher
Elsevier BV
Online
2020-11-13
DOI
10.1016/j.critrevonc.2020.103167
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study
- (2020) Luca Faloppi et al. Targeted Oncology
- Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: results of the multicenter prospective INNOVATE study
- (2020) Andrea Casadei Gardini et al. CLINICAL CANCER RESEARCH
- Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib
- (2020) Andrea Casadei-Gardini et al. MEDICINE
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-based therapies for hepatocellular carcinoma
- (2020) David J. Pinato et al. ONCOGENE
- The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
- (2020) Francesco Caputo et al. PLoS One
- Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
- (2020) Won Jin Ho et al. Journal for ImmunoTherapy of Cancer
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin
- (2019) Serena De Matteis et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort
- (2019) Bernhard Scheiner et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials
- (2019) Andrea Casadei Gardini et al. OncoTargets and Therapy
- Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma
- (2019) Jian Chen et al. TRENDS IN MOLECULAR MEDICINE
- Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
- (2019) M. Moehler et al. OncoImmunology
- ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
- (2019) Giorgia Marisi et al. Cancers
- Hepatotoxicity of immune check point inhibitors: Approach and management
- (2019) Ana Lleo et al. DIGESTIVE AND LIVER DISEASE
- LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
- (2019) A-L Cheng et al. ANNALS OF ONCOLOGY
- Gene Therapy for Liver Cancers: Current Status from Basic to Clinics
- (2019) Kenya Kamimura et al. Cancers
- Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
- (2019) Mubalake Abudoureyimu et al. Frontiers in Oncology
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
- (2019) David Tai et al. Cancers
- Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma
- (2018) Matteo Canale et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma
- (2018) Chun Jye Lim et al. GUT
- Double-Dose Adenovirus-Mediated Adjuvant Gene Therapy Improves Liver Transplantation Outcomes in Patients with Advanced Hepatocellular Carcinoma
- (2018) Ruidong Zhu et al. HUMAN GENE THERAPY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.
- (2018) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
- (2018) Giorgia Marisi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma
- (2018) Michael J Flynn et al. HEPATOLOGY
- Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
- (2017) Andrea Casadei Gardini et al. EUROPEAN JOURNAL OF CANCER
- Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data
- (2017) Wenjun Wang et al. INTERNATIONAL JOURNAL OF CANCER
- New development in CAR-T cell therapy
- (2017) Zhenguang Wang et al. Journal of Hematology & Oncology
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
- (2017) So Young Yoo et al. MEDIATORS OF INFLAMMATION
- Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses
- (2017) Valerie Chew et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
- (2017) Giovan Giuseppe Di Costanzo et al. Targeted Oncology
- Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
- (2017) Andrea Casadei Gardini et al. Oncotarget
- Immunotherapeutic approaches for hepatocellular carcinoma
- (2017) Vito Longo et al. Oncotarget
- Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
- (2017) Andrea Casadei Gardini et al. Scientific Reports
- eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
- (2016) Luca Faloppi et al. Biomed Research International
- Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib
- (2015) Andrea Casadei Gardini et al. EXPERT OPINION ON PHARMACOTHERAPY
- Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
- (2015) Antonio Gnoni et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
- (2014) Luca Faloppi et al. BMC CANCER
- VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
- (2014) Mario Scartozzi et al. INTERNATIONAL JOURNAL OF CANCER
- The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
- (2014) Marco D'Anzeo et al. MOLECULES
- Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey
- (2014) Daniele Santini et al. PLoS One
- Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice
- (2013) Jean-Philippe Pradere et al. HEPATOLOGY
- A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma
- (2013) Xiaozhou Yu et al. JOURNAL OF CLINICAL IMMUNOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
- (2012) Y. Sawada et al. CLINICAL CANCER RESEARCH
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
- (2012) Hang Li et al. HEPATOLOGY
- The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
- (2012) Mario Scartozzi et al. PLoS One
- Augmenting the Antitumor Effect of TRAIL by SOCS3 with Double-Regulated Replicating Oncolytic Adenovirus in Hepatocellular Carcinoma
- (2011) Rui-Cheng Wei et al. HUMAN GENE THERAPY
- Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
- (2011) Mario Scartozzi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma
- (2010) B Sangro et al. CANCER GENE THERAPY
- Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options
- (2010) Luca Faloppi et al. CANCER TREATMENT REVIEWS
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma
- (2009) Hirofumi Shirakawa et al. CANCER SCIENCE
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
- (2009) Dong-Ming Kuang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Neither Multiple Tumors Nor Portal Hypertension Are Surgical Contraindications for Hepatocellular Carcinoma
- (2008) Takeaki Ishizawa et al. GASTROENTEROLOGY
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
- (2008) Byeong-Ho Park et al. LANCET ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started